切换至 "中华医学电子期刊资源库"

中华卫生应急电子杂志 ›› 2025, Vol. 11 ›› Issue (03) : 165 -169. doi: 10.3877/cma.j.issn.2095-9133.2025.03.007

论著

乳腺癌保乳术后放疗致急性放射性皮炎风险预测模型构建及验证
李兴研, 郜业发()   
  1. 721013 陕西宝鸡,宝鸡高新医院乳腺科
  • 收稿日期:2025-02-19 出版日期:2025-06-18
  • 通信作者: 郜业发

Establishment and validation of a risk prediction model for acute radiation dermatitis after breast-conserving surgery for breast cancer

Xingyan Li, Yefa Gao()   

  1. Department of Breast Surgery, Baoji High-tech Hospital, Baoji 721013, China
  • Received:2025-02-19 Published:2025-06-18
  • Corresponding author: Yefa Gao
引用本文:

李兴研, 郜业发. 乳腺癌保乳术后放疗致急性放射性皮炎风险预测模型构建及验证[J/OL]. 中华卫生应急电子杂志, 2025, 11(03): 165-169.

Xingyan Li, Yefa Gao. Establishment and validation of a risk prediction model for acute radiation dermatitis after breast-conserving surgery for breast cancer[J/OL]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2025, 11(03): 165-169.

目的

构建乳腺癌保乳术后放疗致急性放射性皮炎(ARD)发生风险预测模型并验证其效果。

方法

选择宝鸡高新医院乳腺科于2020年1月至2024年10月接受乳腺癌保乳术后放疗患者123例作为研究对象,按照7:3比例分别纳入训练集(n=86)、验证集(n=37)。根据训练集患者是否发生ARD分为ARD组与无ARD组。多因素Logistic回归分析ARD发生危险因素,构建预测模型,采用受试者工作特征曲线(ROC)验证该模型在临床应用中的价值。

结果

接受乳腺癌保乳术后放疗患者86例,发生ARD患者67例,发生率为77.91%。经单因素分析,ARD组和无ARD组体重指数、吸烟史、饮酒史、合并高血压、合并冠心病、病理类型、肿瘤-淋巴结-转移(TNM)分期、三阴性乳腺癌、人表皮生长因子受体-2(HER2)、雌激素受体(ER)和孕激素受体(PR)比较差异无统计学意义(P>0.05);ARD组年龄显著低于无ARD组[(42.31±7.67)比(56.27±9.98),P<0.001];ARD组合并糖尿病占比显著高于无ARD组[(34.33%比10.53%),P<0.05];ARD组营养不足占比显著高于无ARD组[(43.28%比10.53%),P<0.01];ARD组放疗剂量显著高于无ARD组[(57.82±3.24)比(48.97±4.35),P<0.001]。多因素Logistic回归分析结果显示,年龄、营养状况、合并糖尿病、放疗剂量,为影响放疗致ARD发生的独立危险因素(P<0.05)。构建放疗致ARD预测模型:P=-2.22-2.35×年龄+1.75×营养状况+2.68×合并糖尿病+1.99×放疗剂量。采用ROC曲线验证结果显示,曲线下面积为0.876(P=0.000,95%CI:0.828~0.924),敏感度89.90%,特异度71.00%。

结论

年龄、营养状况、合并糖尿病和放疗剂量是影响乳腺癌保乳术后放疗致ARD发生的重要因素,根据上述因素拟定相应的风险预测模型,且该模型预测效果良好,值得进一步深入分析。

Objective

To explore the establishment and validation of a risk prediction model for acute radiation dermatitis (ARD) after breast-conserving surgery for breast cancer.

Methods

A total of 123 patients who received radiotherapy after breast-conserving surgery for breast cancer in our hospital from January 2020 to October 24 were selected as the study subjects, and were included in the training set (n=86) and the validation set (n=37) according to the ratio of 7:3. According to whether patients in the training set have developed ARD, they were divided into the ARD group and the non ARD group. The occurrence of ARD in patients was recorded, and multivariate logistic regression analysis was conducted to identify risk factors for ARD, to construct a predictive model, and to validate the value of the model in clinical applications using ROC curves.

Results

Of the 86 patients who received radiotherapy after breast-conserving surgery for breast cancer, 67 patients developed ARD (77.91%). By univariate analysis, there was no significant difference between ARD group and non ARD group in body mass index, smoking history, drinking history, hypertension, coronary heart disease, pathological type, TNM stage, triple negative breast cancer, HER2, ER and PR (P>0.05). The age in ARD group was significantly lower than that in non ARD group (42.31±7.67 vs 56.27±9.98, P<0.001); The ARD group combined with diabetes was significantly higher non ARD (34.33% vs 10.53%, P<0.05); The ARD group proportion of malnutrition was significantly higher non ARD group (43.28% vs 10.53%, P<0.01); The ARD group radiation dose was significantly higher non ARD group (57.82±3.24 vs 48.97±4.35, P<0.001). Multivariate logistic regression analysis showed that age, nutritional status, combined diabetes, radiotherapy dose entered the regression model (P<0.05), which were independent risk factors for the occurrence of radiation-induced ARD. A prediction model of radiation-induced ARD was established: P=-2.22-2.35×age+1.75×nutritional status+2.68×combined diabetes+1.99×radiation dose. The ROC curve was used to validate the predictive value of the above model for ARD occurrence. The results showed that the area under the curve was 0.876 (P=0.000, 95%CI0.828-0.924), with a sensitivity of 89.90% and a specificity of 71.00%.

Conclusion

Age, nutritional status, combined diabetes, radiation dose are important factors that affect the occurrence of ARD caused by radiotherapy after breast-conserving surgery for breast cancer. According to the above factors, the corresponding risk prediction model is developed, and the prediction effect of the model is good, which is worth further analysis.

表1 放疗致ARD发生单因素分析(例)
图1 ARD和无ARD患者连续变量ROC曲线
表2 多因素分析赋值表
表3 放疗致ARD多因素分析及风险预测模型构建
图2 ROC曲线验证上述模型对ARD发生验证分析
[1]
范蕾,黄纪程,李尧,等.老年与非老年女性乳腺癌患者临床病理特征和影响预后因素的差异分析[J].中华老年医学杂志, 2024, 43(9): 1162-1173.
[2]
Kunkler IH, Williams LJ, Jack WJL, et al. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer[J]. N Engl J Med, 2023, 388(7): 585-594.
[3]
张庆怀,韩阿蒙,杨森,等.乳腺癌患者保乳术后五种放疗技术的疗效比较研究[J].实用肿瘤学杂志, 2023, 37(3): 224-229.
[4]
Wang RJ, Liu HY, Guo LF, et al. 21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer[J]. Breast Cancer, 2024, 31(6): 1156-1166.
[5]
杨文博,孙云川,杨洪娟,等.清热生肌膏对乳腺癌大鼠放射治疗后急性放射性皮炎发生率、ICM-1及新生血管生成的影响[J].广西医科大学学报, 2023, 40(8): 1299-1305.
[6]
邹妮倩,林毅,汪真辉,等.土黄连外洗液对乳腺癌急性放射性皮炎的疗效观察[J].中医肿瘤学杂志, 2022, 4(5): 17-22.
[7]
Jin KR, Luo JR, Yu XL, et al. Hypofractionated radiotherapy with simultaneous tumor bed boost (Hi-RISE) in breast cancer patients receiving upfront breast-conserving surgery: study protocol for a phase III randomized controlled trial[J]. Radiat Oncol, 2024, 19(1): 62.
[8]
魏南,叶明,谢华英.早期乳腺癌保乳术后行全乳大分割同步瘤床加量放疗的临床分析[J].肿瘤, 2022, 42(8): 552-561.
[9]
潘明,裴玲玲,王莹.医用射线抗护喷剂联合德莫林乳膏治疗乳腺癌患者放射性皮肤损伤疗效观察[J].新乡医学院学报, 2023, 40(8): 765-768.
[10]
李丹,范学武,丁蕾,等.发光二极管在乳腺癌患者急性放射性皮炎防治中的应用[J].辐射研究与辐射工艺学报, 2022, 40(2): 54-59.
[11]
于爱萍,杨柳,郭睿.三黄油联合喜疗妥治疗乳腺癌患者放疗中急性放射性皮炎临床观察[J].肿瘤基础与临床, 2021, 34(2): 183-184.
[12]
周严红,耿文慧,李萌萌,等.皮肤温度监测在女性乳腺癌术后放疗期间放射性皮炎风险预警中的应用[J].中华放射医学与防护杂志, 2024, 44(2): 127-132.
[13]
朱乐莎,张遵浩,田龙.乳腺癌患者急性放射性皮炎关联规则预测模型创建[J].辐射研究与辐射工艺学报, 2025, 43(1): 65-72.
[14]
耿文慧,周严红,卢霄蒙,等.乳腺癌术后放疗患者放射区皮肤温度与放射性皮炎程度的相关性分析[J].现代中西医结合杂志, 2023, 32(2): 257-260.
[15]
庄雅靖,王宁,郭燕陶,等.乳腺癌根治术后VMAT大分割放疗的剂量学分析及疗效研究[J].重庆医学, 2024, 53(16): 2448-2452, 2457.
[1] 明昊, 宋宏萍, 白誉誉, 党晓智, 赵阳, 程燕妮, 王琪, 肖迎聪. 自动乳腺超声联合临床病理特征预测Luminal B 型乳腺癌术后复发风险的临床研究[J/OL]. 中华医学超声杂志(电子版), 2025, 22(04): 337-347.
[2] 赵长燕, 张明慧, 陆春燕. FOXC1和claudin-4在三阴性乳腺癌中的表达及其与肿瘤微环境和炎症相关因子的关系[J/OL]. 中华乳腺病杂志(电子版), 2025, 19(02): 97-102.
[3] 张建, 陈小军, 杨建, 陈新杰. 肌筋膜松解术对乳腺癌根治术后患者恢复效果的随机对照研究[J/OL]. 中华乳腺病杂志(电子版), 2025, 19(02): 103-107.
[4] 李乐桐, 林加曼, 王强. 1-磷酸鞘氨醇受体1 在乳腺癌患者中的表达及其对预后和免疫浸润的影响[J/OL]. 中华危重症医学杂志(电子版), 2025, 18(02): 105-114.
[5] 安宁, 陈健, 张京伟, 习一清. 长链非编码RNA 乳腺癌抗雌激素耐药基因4 在常见肿瘤进展中的作用[J/OL]. 中华普通外科学文献(电子版), 2025, 19(03): 203-208.
[6] 杨娜, 胡刚, 潘越. 保乳术和改良根治术后行新辅助化疗对三阴性乳腺癌血清标志物影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(03): 345-348.
[7] 何友新, 韩林荟, 杨贺庆. 新辅助化疗分别联合保乳术和改良根治术治疗Ⅱ、Ⅲ期乳腺癌的应用效果[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 184-187.
[8] 何海霞, 白守民. 放疗在肌层浸润性膀胱癌保膀胱治疗中的应用现状及优化减毒策略[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(03): 288-295.
[9] 刘军, 王子函, 李梦新, 高国璇, 蒋宏传, 沈光前. 单孔机器人保乳手术初步探索[J/OL]. 中华腔镜外科杂志(电子版), 2025, 18(03): 162-165.
[10] 罗臻, 韦鹏程, 孙馨, 李照. 肝细胞癌骨转移研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 522-527.
[11] 中国医师协会结直肠肿瘤专业委员会术中放疗协作组. 结直肠癌术中放疗专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(04): 299-306.
[12] 夏长河, 胡旭华, 郑晓红, 刘芳, 王亚轩, 王贵英. 直肠癌腹会阴联合切除(Miles)术后迟发性尿道瘘一例[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(03): 281-283.
[13] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-结肠癌(2024版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(02): 97-113.
[14] 黑墨然, 马慧娥, 郝嫣然, 徐泽成, 郭义, 陈泽林, 李丹, 陈波, 赵雪, 赵天易. 不同针灸疗法治疗乳腺癌术后淋巴水肿相关症状的Meta 分析及其腧穴配伍的网状Meta 分析[J/OL]. 中华针灸电子杂志, 2025, 14(02): 58-65.
[15] 庞心念, 蒋添, 徐贝贝, 杨天瑶, 李伟, 陈禄凑. 超声特征联合临床病理早期预测乳腺癌新辅助化疗疗效的应用价值[J/OL]. 中华诊断学电子杂志, 2025, 13(02): 89-96.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?